Incyte Had a Bad Week. Investors Are Used to It.
Incyte’s quest for its next big thing ended in disappointment—and a stock tumble—this past week. Unfortunately, the problems ...
Why Incyte Stock Was Tanking This Week
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock ...
Incyte (INCY) was downgraded to a Hold Rating at William Blair
Incyte (INCY – Research Report) received a Hold rating and price target from William Blair analyst Matt Phipps today. The company’s shares ...
Clinical Trials Arena on MSN3d
Incyte stock hit by 11% despite paediatric dermatology trials hitting target
The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.
Incyte Corp. stock underperforms Monday when compared to competitors
Shares of Incyte Corp. INCY slid 8.62% to $62.01 Monday, on what proved to be an all-around positive trading session for the ...
Incyte price target lowered to $72 from $74 at Truist
Truist lowered the firm’s price target on Incyte (INCY) to $72 from $74 and keeps a Hold rating on the shares. Following the ...
Incyte Leads S&P 500 Decliners on Skin Condition Drug Trial Results
Shares of Incyte sank Monday, making it the biggest decliner in the S&P 500 after the release of its latest clinical trial.
Fierce Biotech7d
Incyte posts phase 3 skin condition wins but details disappoint, sinking stock
Incyte has delivered a pair of pivotal wins for an oral JAK inhibitor in an inflammatory skin condition. But with the placebo ...
William Blair Issues Optimistic Estimate for Incyte Earnings
Investment analysts at William Blair increased their Q2 2025 EPS estimates for shares of Incyte in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps now expects that the ...
Incyte (INCY) Receives a Hold from Truist Financial
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Hold rating on Incyte (INCY – Research Report), with a ...
Top Stock Movers Now: Intel, Netflix, Incyte, and More
U.S. equities were mixed at midday, with positive news on retail sales eased continuing concerns about tariffs.
Yahoo Finance3d
Why Incyte Stock Was Tanking This Week
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (NASDAQ: INCY) stock over the past few days. The gloom this produced was pushing the biotech's ...